Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

We Haven’t Ruled Out Drug Price Increases, Says Regeneron’s Schleifer

Executive Summary

In an exclusive interview, one of the most direct CEOs in the industry, Regeneron’s Len Schleifer, clarifies his attitude to drug pricing and growing internal innovation.

You may also be interested in...



US Drug Pricing Challenges Poised To Impact Pharma Growth, Leerink Warns

Drug price increases have contributed significantly to US revenue growth, about 61% for the 45 largest pharmaceutical products sold over the last three years, according to an analysis by Leerink. Investors should brace for declining growth rates for certain products that generate the bulk of their sales in the US, analyst Geoffrey Porges warned.

Sanofi/Regeneron's IO Springboard Libtayo Cleared For Skin Cancer

In addition to skin cancer, the PD-1 inhibitor cemiplimab is being positioned for a range of other tumor types with Phase III studies ongoing in lung and cervical cancers.

Regeneron And Bluebird Team Up In Cell Therapy "Joint Venture"-Style Deal

Regeneron will make a $100m equity investment in bluebird to collaborate on the discovery of antibodies and T cell receptors, with the hope of building out in immuno-oncology and overcoming some of the early cell therapy challenges. Regeneron's business development chief talks to Scrip about its strategy.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC123971

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel